Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Protalix Biotherapeutics (PLX)

Protalix Biotherapeutics (PLX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 29,854
  • Shares Outstanding, K 148,382
  • Annual Sales, $ 34,240 K
  • Annual Income, $ -26,460 K
  • 60-Month Beta 2.73
  • Price/Sales 0.90
  • Price/Cash Flow N/A
  • Price/Book N/A
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.05
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date 11/07/19
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/19
See More
  • Average Estimate -0.03
  • Number of Estimates 2
  • High Estimate 0.01
  • Low Estimate -0.06
  • Prior Year 0.07
  • Growth Rate Est. (year over year) -142.86%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.17 +16.74%
on 10/15/19
0.47 -57.57%
on 10/17/19
+0.02 (+13.55%)
since 10/14/19
3-Month
0.17 +17.29%
on 10/14/19
0.47 -57.57%
on 10/17/19
-0.05 (-18.65%)
since 08/14/19
52-Week
0.17 +17.29%
on 10/14/19
0.60 -66.77%
on 02/01/19
-0.22 (-52.52%)
since 11/14/18

Most Recent Stories

More News
Protalix (PLX) Reports Q3 Loss, Tops Revenue Estimates

Protalix (PLX) delivered earnings and revenue surprises of 50.00% and 22.83%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

PLX : 0.20 (unch)
Protalix BioTherapeutics Reports Third Quarter 2019 Results and Provides Corporate Update

Protalix BioTherapeutics, Inc. (NYSE American: PLX) (TASE: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by...

PLX : 0.20 (unch)
Protalix (PLX) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

Protalix (PLX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

PLX : 0.20 (unch)
Protalix BioTherapeutics to Release Third Quarter 2019 Financial Results and Business Update on November 7, 2019

Protalix BioTherapeutics, Inc. (NYSE American: PLX) (TASE: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by...

PLX : 0.20 (unch)
Protalix BioTherapeutics Announces Positive 12-Month Interim Data From the BRIDGE Phase III Open Label Switch-over Study of Pegunigalsidase Alfa for the Treatment of Fabry Disease

Protalix BioTherapeutics, Inc. (NYSE American: PLX) (TASE: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by...

PLX : 0.20 (unch)
Protalix Completes Enrollment in Third Fabry Disease Study

Protalix (PLX) completes enrollment in another phase III study of pegunigalsidase alfa (PRX 102) to treat Fabry disease.

PFE : 36.53 (-0.19%)
SNY : 45.05 (-1.25%)
PLX : 0.20 (unch)
ACOR : 1.81 (-6.22%)
Protalix BioTherapeutics and Chiesi Group Complete Enrollment in the Third Phase III Clinical Trial of pegunigalsidase alfa (PRX--102) for the Treatment of Fabry Disease

Protalix BioTherapeutics, Inc. (NYSE American: PLX) (TASE: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by...

PLX : 0.20 (unch)
Protalix BioTherapeutics Receives Listing Deficiency Letter from NYSE American

Protalix BioTherapeutics, Inc. (NYSE American:PLX) (TASE:PLX), a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins including a late-stage clinical...

PLX : 0.20 (unch)
Protalix BioTherapeutics Focuses on Evaluating and Pursuing Alternatives to Maximize Shareholder Value through Refinancing & Strategic Partnerships

Protalix BioTherapeutics, Inc. (NYSE American: PLX) (TASE: PLX), a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary...

PLX : 0.20 (unch)
Shlomo Yanai Resigns as Chairman of the Board of Protalix BioTherapeutics

Protalix BioTherapeutics, Inc. (NYSE American:PLX) (TASE:PLX) today announced that Shlomo Yanai has resigned from the Company's Board of Directors for personal reasons, effective today. Mr. Yanai has served...

PLX : 0.20 (unch)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 80% Sell with a Strengthening short term outlook on maintaining the current direction.

Longer term, the trend strength is Strong. Long term indicators fully support a continuation of the trend.

The market is in highly oversold territory. Beware of a trend reversal.

See More Share

Trade PLX with:

Business Summary

Protalix is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based expression system, ProCellEx(R). Protalix's unique expression system presents a proprietary method for developing recombinant...

See More

Key Turning Points

2nd Resistance Point 0.21
1st Resistance Point 0.21
Last Price 0.20
1st Support Level 0.20
2nd Support Level 0.19

See More

52-Week High 0.60
Fibonacci 61.8% 0.44
Fibonacci 50% 0.39
Fibonacci 38.2% 0.33
Last Price 0.20
52-Week Low 0.17

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar